Treatment decisions guided by real-time genetic information from blood
In the ongoing effort to match cancer therapies to the patients most likely to benefit from them, two diagnostic companies have deepened a collaboration aimed at making genetic monitoring of advanced breast cancer faster and more accessible. Biodesix and Bio-Rad Laboratories are joining forces to bring a blood-based test for ESR1 mutations through clinical validation and into accredited laboratories, where it could guide treatment decisions for women with hormone-receptor positive breast cancer. The partnership reflects a broader conviction in modern oncology: that understanding how a tumor changes over time, read from the bloodstream rather than the operating table, may be as important as the drugs used to treat it.
- A critical gap exists in oncology care — ESR1 mutations are now central to treatment decisions for a major breast cancer subtype, yet reliable, standardized testing remains fragmented and slow.
- A new class of oral SERD drugs has demonstrated real survival benefits, but without sensitive mutation testing, clinicians cannot fully determine which patients will respond or when resistance is developing.
- Biodesix is stepping in to carry Bio-Rad's droplet digital PCR assay through the demanding clinical validation and regulatory approval process required before any test can reach patients.
- The company plans to offer the test through its own CLIA-CAP accredited laboratory and pursue Medicare and Medicaid reimbursement — the step that will determine whether access is broad or limited.
- The partnership is expected to be showcased at a major molecular pathology conference in Boston in November, signaling the companies' readiness to move from development toward commercial deployment.
Two diagnostic companies announced a deepened collaboration this week that could change how oncologists monitor a specific form of advanced breast cancer. Biodesix, based in Colorado, will lead the clinical development and regulatory submission of a genetic test built on Bio-Rad Laboratories' droplet digital PCR technology — a platform capable of detecting vanishingly small amounts of mutated DNA circulating in a patient's blood.
The test targets mutations in a gene called ESR1, which has become a critical marker in hormone-receptor positive, HER2-negative breast cancer. Patients with this profile now have access to a promising new class of drugs — oral selective estrogen receptor degraders, or SERDs — that have shown measurable survival benefits in trials. But the ability to detect ESR1 mutations quickly and sensitively has lagged behind the drugs themselves.
Biodesix's task is to move Bio-Rad's assay through rigorous U.S. regulatory validation, then offer it through its own accredited laboratory under both CLIA and CAP certification standards. The company will also seek reimbursement from Medicare and Medicaid — a step that will determine whether the test becomes widely accessible or remains out of reach for many patients.
The collaboration extends an existing relationship between the two companies, which already work together on lung cancer diagnostics. For breast cancer, it represents new ground. Both executives framed the expansion as a response to growing clinical demand for real-time genetic monitoring — the kind that tracks how a tumor evolves and whether it is developing resistance to therapy, without requiring repeated tissue biopsies.
The test is not yet available; validation and regulatory clearance still lie ahead. But the companies plan to share more details at the Association for Molecular Pathology conference in Boston in mid-November, and the infrastructure to bring it to market is now in place.
Two diagnostic companies announced a deepened partnership this week that could reshape how doctors monitor a specific type of advanced breast cancer. Biodesix, a Colorado-based diagnostics firm, will now take the lead on developing and validating a new genetic test from Bio-Rad Laboratories designed to detect mutations in a gene called ESR1 from blood samples of cancer patients.
The test itself is built on technology called droplet digital PCR, which Bio-Rad has spent years refining. The machinery—called the QX600 platform—can identify extremely small amounts of mutated DNA circulating in a patient's bloodstream. What makes this partnership significant is not the technology alone, but what it enables clinically. ESR1 mutations have emerged as a critical marker in a subset of breast cancers: those that are hormone-receptor positive but HER2 negative, often abbreviated as HR+/HER2-. These patients now have access to a new class of drugs called oral selective estrogen receptor degraders, or SERDs, which have shown measurable survival benefits in clinical trials.
Until now, testing for these mutations has been fragmented and slow. Biodesix's role is to take Bio-Rad's assay through the rigorous clinical validation process required by U.S. regulators, then submit it for approval. Once cleared, the company plans to offer the test through its own accredited laboratory—one that meets both CLIA and CAP standards, the federal and private certifications that govern clinical testing. The company will also pursue reimbursement from Medicare and Medicaid, a crucial step that determines whether the test becomes accessible to patients or remains a boutique offering.
Scott Hutton, Biodesix's chief executive, framed the expansion as a response to growing demand. ESR1 mutations, he said, have become increasingly important to the oncology market, and clinicians need rapid, sensitive ways to detect them. The partnership also signals confidence in a particular vision of cancer care: one where treatment decisions are guided by real-time genetic information from a patient's blood rather than by static tissue biopsies alone. This approach, sometimes called liquid biopsy, allows doctors to monitor how a tumor is evolving and whether it is developing resistance to therapy.
Biodesix is not new to this space. The company already markets lung cancer tests under the brand names Nodify Lung and IQLung, and it has a long-standing relationship with Bio-Rad in that domain. This breast cancer partnership extends that collaboration into new territory. Steve Kulisch, who oversees product management at Bio-Rad's life science division, noted that the two companies have proven they can work together effectively, and that validating the ESR1 assay will expand their reach into clinical diagnostics for a disease that affects hundreds of thousands of women annually.
The companies plan to present more details about their research and commercial strategy at the Association for Molecular Pathology conference in Boston in mid-November. For now, the partnership represents a bet that personalized medicine in oncology depends not just on better drugs, but on better ways to measure what is happening inside a patient's body. The test is not yet available—validation and regulatory approval still lie ahead—but the infrastructure to bring it to market is now in place.
Citas Notables
ESR1 mutations have become increasingly important to the oncology market, and clinicians need rapid, sensitive ways to detect them.— Scott Hutton, CEO of Biodesix
Validation of the ESR1 assay will expand the companies' combined capabilities in clinical diagnostics, increasing access to sensitive biomarker detection for advanced breast cancer.— Steve Kulisch, VP Product Management, Bio-Rad Laboratories
La Conversación del Hearth Otra perspectiva de la historia
Why does detecting ESR1 mutations matter so much for these particular breast cancer patients?
Because a new generation of drugs called SERDs actually works against these mutations. If you know a patient has them, you know which therapy to use. Without the test, you're guessing.
So this is about matching the right drug to the right patient.
Exactly. And doing it from a blood sample instead of a biopsy means you can check repeatedly, watch how the cancer is changing, catch resistance early.
What's the barrier to adoption right now?
Speed, sensitivity, and access. The test needs to be validated, approved, and covered by insurance. Biodesix is handling all three. Without Medicare reimbursement, most patients never get it.
How does this partnership change the game?
Bio-Rad built the technology. Biodesix knows how to get it through regulators and into clinical labs. Together, they can move faster than either could alone.
What happens if this works?
Thousands of women with advanced breast cancer get better information about their treatment. That's the theory, anyway.